Recurrent coronary disease in HIV-infected patients: role of drug-drug interactions

Br J Clin Pharmacol. 2018 Jul;84(7):1617-1619. doi: 10.1111/bcp.13583. Epub 2018 Apr 16.

Abstract

Cardiovascular disease represents a leading comorbidity in HIV populations. Different factors may contribute to the recurrence of cardiovascular events in HIV‐infected patients. Here, we describe two patients with HIV infection and an acute coronary syndrome who developed in‐stent thrombosis after a percutaneous revascularization procedure. Also, we discuss the potential role of drug interactions between antiretroviral and antiplatelet treatments as a contributing factor for recurrent coronary disease in HIV‐infected patients.

Keywords: HIV infection; coronary disease; drug interactions.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anti-HIV Agents / pharmacology*
  • Anti-HIV Agents / therapeutic use
  • Coronary Artery Disease / therapy*
  • Cytochrome P-450 CYP3A / metabolism
  • Cytochrome P-450 CYP3A Inducers / pharmacology*
  • Cytochrome P-450 CYP3A Inducers / therapeutic use
  • Drug Interactions
  • HIV Infections / drug therapy*
  • Humans
  • Male
  • Middle Aged
  • Percutaneous Coronary Intervention / instrumentation
  • Percutaneous Coronary Intervention / methods
  • Platelet Aggregation Inhibitors / pharmacology*
  • Platelet Aggregation Inhibitors / therapeutic use
  • Recurrence
  • Risk Factors
  • Stents

Substances

  • Anti-HIV Agents
  • Cytochrome P-450 CYP3A Inducers
  • Platelet Aggregation Inhibitors
  • Cytochrome P-450 CYP3A